Floatz logo

lmp1/2 ctls

Leiomyosarcoma

Catherine BollardCell therapyPhase 1Dormant
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
81/ 100

Competitive context

18 Active assets in the Leiomyosarcoma cohort.

Asset / SponsorPhaseRating
Sorafenib
National Cancer Institute (NCI)
Phase 2B
Temsirolimus
National Cancer Institute (NCI)
Phase 2B
Cixutumumab
National Cancer Institute (NCI)
Phase 2B
vx-970
Massachusetts General Hospital
Phase 2B
Olaparib
University Health Network, Toronto
Phase 2CCC

View all 26 →

Same molecule, other indications

lmp1/2 ctls is also rated in:

nasopharyngeal type undifferentiated carcinomaDormant
CCC
Indicative ·
52 / 100
View asset →
Hodgkins lymphomaDormant
CCC
Indicative ·
50 / 100
View asset →
Severe Chronic Active EBV Infection Syndrome (SCAEBV)Dormant
CC
Indicative ·
47 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →